These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22550860)

  • 1. [Metabolic immunocorrection treatment of experimental widespread purulent peritonitis].
    Gostishchev VK; Kosinets VA; Matusevich EA; Adamenko GP
    Eksp Klin Farmakol; 2012; 75(2):42-6. PubMed ID: 22550860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correction of bioenergetic processes in small intestine during experimental widespread purulent peritonitis].
    Kosinets VA
    Eksp Klin Farmakol; 2012; 75(8):39-43. PubMed ID: 23012995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The immune activity of cytoflavine in the treatment of the diffuse septic peritonitis].
    Matusevich EA
    Khirurgiia (Mosk); 2012; (5):72-5. PubMed ID: 22810541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correction of protein-lipid composition in liver mitochondria during experimental widespread purulent peritonitis].
    Kosinets VA; Osochuk SS; Iarotskaia NN
    Eksp Klin Farmakol; 2012; 75(3):31-4. PubMed ID: 22679751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic correction of the lipid-transport system in experimental diffuse purulent peritonitis].
    Kosinets VA
    Vestn Khir Im I I Grek; 2012; 171(3):92-6. PubMed ID: 22880442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Free-radical oxidation in liver during experimental widespread purulent peritonitis].
    Kosinets VA; Iarotskaia NN
    Eksp Klin Farmakol; 2012; 75(10):37-41. PubMed ID: 23240157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antioxidant activity of cytoflavin in experimental diffuse purulent peritonitis].
    Kosinets VA
    Eksp Klin Farmakol; 2010 Jan; 73(1):30-2. PubMed ID: 20184286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immunoregulating action of reamberine and its use in the treatment of duffuse peritonitis].
    Kosinets VA
    Khirurgiia (Mosk); 2013; (7):29-32. PubMed ID: 23887320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic correction of structural changes in adrenal glands during experimental widespread purulent peritonitis].
    Kosinets VA; Fedotov DN
    Eksp Klin Farmakol; 2012; 75(6):44-7. PubMed ID: 22891442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological correction of free radical disturbances and endotoxicosis in patients with diffuse peritonitis at the postoperative period].
    Bagnenko SF; Mirzabaev AT; Batotsyrenov BV; Gorbachev NB; Miroshnichenko VN; Batotsyrenova KhV; Velikiĭ KF
    Vestn Khir Im I I Grek; 2011; 170(5):14-6, 18. PubMed ID: 22238957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Structural changes in heart at experimental widespread purulent peritonitis].
    Kosinets VA; Samsonova IV; Ryzhkovskaia EL
    Khirurgiia (Mosk); 2012; (3):69-73. PubMed ID: 22678541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antioxidant therapy in discirculatory encephalopathy].
    Antipenko EA; Gustov AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):53-5. PubMed ID: 21465819
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacologic correction of hypoxia in patients with acute cerebral failure due to acute poisoning with carbon monoxide and combustion products].
    Shilov VV; Vasil'ev SA; Kuznetsov OA; Batotsyrenov BV; Loladze AT
    Med Tr Prom Ekol; 2012; (6):22-7. PubMed ID: 22997755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The correction of the mitochondrial lipid spectre in liver by the experimental peritoniti].
    Kosinets VA; Osochuk SS; Iarotskaia NN
    Khirurgiia (Mosk); 2012; (2):60-3. PubMed ID: 22678477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correction of a reperfusion dysfunction in acute intestinal obstruction].
    Bagnenko SF; Sinenchenko GI; Kurygin AA; Chupris VG
    Vestn Khir Im I I Grek; 2008; 167(4):32-5. PubMed ID: 18942433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positive effect of cytoflavin on metabolic status changes in patients with burn disorder].
    Polutova NV; Ostrovskiĭ NV; Romantsov MG; Chesnokova NP
    Eksp Klin Farmakol; 2011; 74(7):33-7. PubMed ID: 21894767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacotherapy of basic clinical presentations of chronic brain ischemia].
    Madzhidova EN; Usmanova DD; Baĭtursunova ZhM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(8 Pt 1):60-2. PubMed ID: 21946144
    [No Abstract]   [Full Text] [Related]  

  • 18. [The results of using cytoflavin in conservative treatment of patients with obliterating atherosclerosis of the lower extremity vessels].
    Bogomolov MS; Sedov VM; Edovina LN; Luk'ianov IuV; Slobodianiuk VV
    Vestn Khir Im I I Grek; 2011; 170(1):43-6. PubMed ID: 21506354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of cytoflavin into the complex intensive therapy of acute cerebral insufficiency caused by poisoning].
    Vasilyev S; Shilov V; Aleksandrov M; Batotsyrenov B; Loladze A
    Georgian Med News; 2012 Feb; (203):22-9. PubMed ID: 22466536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of multimodal effect of cytoflavin in the acute brain stroke in patients with metabolic syndrome].
    Asadullaev MM; Saidvaliev FS; Shermukhamedova FK; Rizvonov ZhK; Vakhabova NM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10):24-7. PubMed ID: 23250593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.